Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03591458 · ClinicalTrials.gov registry record · Phase 2
Amitriptyline in Treating Hypoglycemia
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03591458 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 2 participants.
The verdict
NCT03591458, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Patients with type 1 diabetes mellitus (T1DM) commonly experience hypoglycemia and develop impaired awareness of hypoglycemia. Many patients using continuous glucose monitoring (CGM) system to mitigate these complications, but continue to spend a significant amount of time in hypoglycemia. The long-term goal is to develop novel and readily available therapeutic approaches to improve hypoglycemia course and awareness in T1DM patients. The objective of this study is to determine whether amitriptyline will improve hypoglycemia course and the ability to recognize hypoglycemic events in T1DM patients who are using CGM.
Interventions
- DRUG Placebo
- DRUG Amitriptyline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2019-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03591458
The ClinicalTrials.gov registry entry for NCT03591458 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03591458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03591458 about?
NCT03591458 is a clinical study titled "Amitriptyline in Treating Hypoglycemia". Patients with type 1 diabetes mellitus (T1DM) commonly experience hypoglycemia and develop impaired awareness of hypoglycemia. Many patients using continuous glucose monitoring (CGM) system to mitigate these complications, but continue to spend a significant amount of time in hypoglycemia. The long-...
What is the current status of trial NCT03591458?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2018-08-01. Estimated completion is 2019-06-03.
What interventions are being tested in trial NCT03591458?
The interventions under investigation include: Placebo (DRUG), Amitriptyline (DRUG).
Who is sponsoring clinical trial NCT03591458?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.